| FF/VI 100/25 μg | FP/SAL 500/50 μg | Least squares mean difference (95% CI) | |
| Subjects n | 266 | 262 | |
| wm (0–24 h) FEV1 (mL) on day 84 (primary end-point) | 130±222 | 108±221 | 22 (-18–63)¶ |
| Trough FEV1 (mL) on day 85 (secondary end-point) | 111±241 | 88±241 | 23 (-20–66) |
| SGRQ total score at week 12 | -4.3±11.8 | -3.0±11.8 | -1.3 (-3.5–0.8) |
| wm (0–4 h) FEV1 (mL) on day 84# | 205±226 | 162±227 | 43 (2–83) |
| wm (0–12 h) FEV1 (mL) on day 84# | 175±225 | 128±225 | 46 (5–88) |
| wm (12–24 h) FEV1 (mL) on day 84# | 88±229 | 87±229 | 1 (-41–43) |
Data are presented as mean±sd, unless otherwise stated. FF: fluticasone furoate; VI: vilanterol trifenatate; FP: fluticasone propionate; SAL: salmeterol; wm: weighted mean; FEV1: forced expiratory volume in 1 s; SGRQ: St George's Respiratory Questionnaire. #: post hoc analyses; ¶: p=0.282.